Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 31.69M 22.56M 19.72M 18.19M 16.72M 2.17B 32.23M 217M 85.22M 1.06B 84.71M 82.85M 3.66B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 31.46M 22.39M 19.58M 18.06M 16.6M 2.15B 32M 216M 84.6M 1.05B 84.1M 82.25M 3.63B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
1 day-3.57%
Current month+8.00%
1 month+42.11%
3 months+22.73%
6 months-25.00%
Current year-20.59%
1 week 0.13
Extreme 0.13
0.14
1 month 0.09
Extreme 0.09
0.14
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.22
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Date Insider Type Main position Quantity % Market Cap.
Jun. 04Sell

Director

100,000 0.0557%
Jun. 04Sell

Director

100,000 0.0557%
Jun. 04Sell

Director

500,000 0.2786%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%0.00%-27.03%+125.00% 22.55M
+0.32%-4.74%+50.08%+159.03% 1,028B
-1.97%-5.55%+60.33%+56.40% 611B
+0.64%-2.20%+32.62%+83.33% 432B
+0.98%-1.40%+29.49%+23.12% 323B
-0.34%-3.10%+27.00%+43.66% 277B
+1.63%-11.76%+19.72%+23.20% 257B
+3.39%+2.29%-23.68%-38.33% 217B
+0.89%-2.41%+22.77%+57.62% 192B
+1.33%-2.72%+21.15%+70.53% 161B
Average +0.42%-5.06%+21.25%+60.36% 349.84B
Weighted average by Cap. +0.44%-5.52%+36.35%+78.22%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.35
Net income -1.71M -1.22M -1.06M -980K -901K -117M -1.74M -11.7M -4.59M -57.16M -4.56M -4.46M -197M -3.53M -2.51M -2.2M -2.03M -1.86M -242M -3.59M -24.21M -9.5M -118M -9.44M -9.24M -408M
Net Debt -113K -80.18K -70.1K -64.67K -59.44K -7.71M -115K -772K -303K -3.77M -301K -295K -13M -231K -164K -143K -132K -122K -15.79M -234K -1.58M -620K -7.72M -616K -603K -26.6M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
26-07-15 CA$0.1350 -3.57% 466,000
26-07-14 CA$0.1400 0.00% 50,500
26-07-13 CA$0.1400 +3.70% 39,884
26-07-09 CA$0.1350 0.00% 25,500
26-07-08 CA$0.1350 -6.90% 19,637

Annual profits - Rate of surprise